Deciphering the Enigma: NAP (CP201) the Active ADNP Drug Candidate Enters Cells by Dynamin-Associated Endocytosis

J Mol Neurosci. 2020 Jul;70(7):993-998. doi: 10.1007/s12031-020-01632-6.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Amino Acid Motifs
  • Amyotrophic Lateral Sclerosis / prevention & control
  • Animals
  • Axonal Transport / drug effects
  • Cell Line, Tumor
  • Disease Models, Animal
  • Dynamins / physiology*
  • Endocytosis*
  • Homeodomain Proteins
  • Hydrazones / pharmacology
  • Mice
  • Mice, Knockout
  • Microtubule-Associated Proteins / drug effects
  • Microtubule-Associated Proteins / metabolism
  • Microtubules / drug effects*
  • Microtubules / metabolism
  • Microtubules / ultrastructure
  • Nerve Tissue Proteins / deficiency
  • Neurons / drug effects
  • Neuroprotective Agents / pharmacokinetics*
  • Oligopeptides / pharmacokinetics*
  • Parkinsonian Disorders / drug therapy
  • Tauopathies / drug therapy
  • Tauopathies / prevention & control

Substances

  • ADNP protein, human
  • Adnp protein, mouse
  • Homeodomain Proteins
  • Hydrazones
  • Microtubule-Associated Proteins
  • N'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide
  • Nerve Tissue Proteins
  • Neuroprotective Agents
  • Oligopeptides
  • Dynamins
  • davunetide

Supplementary concepts

  • Amyotrophic lateral sclerosis 1